Latest & greatest articles for screening

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on screening or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on screening and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for screening

3401. Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection. (Abstract)

Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection. Chlamydia trachomatis is a frequent cause of pelvic inflammatory disease. However, there is little information from clinical studies about whether screening women for cervical chlamydial infection can reduce the incidence of this serious illness.We conducted a randomized, controlled trial to determine whether selective testing for cervical chlamydial infection prevented pelvic inflammatory disease. Women (...) -to-screen analysis to compare the incidence of pelvic inflammatory disease in the two groups of women.Of the 2607 eligible women, 1009 were randomly assigned to screening and 1598 to usual care. A total of 645 women in the screening group (64 percent) for chlamydia; 7 percent tested positive and were treated. At the end of the follow-up period, there had been 9 verified cases of pelvic inflammatory disease among the women in the screening group and 33 cases among the women receiving usual care (relative

1996 NEJM Controlled trial quality: predicted high

3402. Randomised study of screening for colorectal cancer with faecal-occult-blood test. (Abstract)

Randomised study of screening for colorectal cancer with faecal-occult-blood test. Case-control studies and a voluntary-based follow-up study have suggested that repeated screening with faecal-occult-blood (FOB) tests can lead to a reduction in mortality from colorectal cancer (CRC). The aim of this randomised study was to compare mortality rates after FOB tests every 2 years during a 10-year period with those of unscreened similar controls.140,000 people aged 45-75 years lived in Funen (...) , Denmark, in August, 1985, and were considered for inclusion in our study. Before randomisation we excluded individuals who had CRC or precursor adenomas and those who had taken part in a previous pilot study. Randomisation of 137,485 people in blocks of 14 allocated three per 14 to the screening group (30,967), three per 14 to the control group (30,966), and eight not to be enrolled in the study (75,552). Controls were not told about the study and continued to use health-care facilities as normal

1996 Lancet Controlled trial quality: uncertain

3403. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. (Abstract)

Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. There is growing evidence that faecal-occult-blood (FOB) screening may reduce colorectal cancer (CRC) mortality, but this reduction in CRC mortality has not been shown in an unselected population-based randomised controlled trial. The aim of this study was to assess the effect of FOB screening on CRC mortality in such a setting.Between February, 1981, and January, 1991, 152,850 people aged 45-74 years who lived (...) in the Nottingham area of the UK were recruited to our study. Participants were randomly allocated FOB screening (76,466) or no screening (controls; 76,384). Controls were not told about the study and received no intervention. Screening-group participants were sent a Haemoccult FOB test kit with instructions from their family doctor. FOB tests were not rehydrated and dietary restrictions were imposed only for retesting borderline results. Individuals with negative FOB tests at the first screening, together

1996 Lancet Controlled trial quality: predicted high

3404. Screening for hepatitis B in pregnancy

Screening for hepatitis B in pregnancy Screening for hepatitis B in pregnancy Screening for hepatitis B in pregnancy Best L Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Best L. Screening for hepatitis B in pregnancy. Southampton: Wessex Institute for Health Research and Development (WIHRD) 1996 Authors' objectives There is a proposal (...) for all pregnant women to be screened for hepatitis B surface antigen (HBsAg) in the antenatal period. Neonates who are likely to have been infected with the hepatitis B virus (ie those with HBsAg positive mothers) can be immunised in their first 6 months of life. The author evaluates this proposal. Authors' conclusions Universal screening is strongly recommended. The author points out that there are plans to implement routine hepatitis B vaccination, and that, since vaccination would probably take

1996 Health Technology Assessment (HTA) Database.

3405. Factor V Leiden screening in oral contraceptive users

Factor V Leiden screening in oral contraceptive users Factor V Leiden screening in oral contraceptive users Factor V Leiden screening in oral contraceptive users Bryant J Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Bryant J. Factor V Leiden screening in oral contraceptive users. Southampton: Wessex Institute for Health Research (...) and Development (WIHRD) 1996 Authors' objectives Factor V Leiden is the most common hereditary blood coagulation disorder. It is present in 3-8% of a healthy white population and it is associated with venous thrombosis especially in oral contraceptive users. The author evaluates a proposal to introduce screening for Factor V Leiden mutation in oral contraceptive users who have a first degree relative who has suffered venous thrombosis, and deter test positives from oral contraception, in comparison

1996 Health Technology Assessment (HTA) Database.

3406. Breast cancer screening in Catalonia: cost-effectiveness, health care impact and cost of the treatment of breast cancer

Breast cancer screening in Catalonia: cost-effectiveness, health care impact and cost of the treatment of breast cancer Breast cancer screening in Catalonia: cost-effectiveness, health care impact and cost of the treatment of breast cancer Breast cancer screening in Catalonia: cost-effectiveness, health care impact and cost of the treatment of breast cancer Borras J M Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation (...) of the quality of this assessment has been made for the HTA database. Citation Borras J M. Breast cancer screening in Catalonia: cost-effectiveness, health care impact and cost of the treatment of breast cancer. Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA). IN96010. 1996 Authors' objectives This report has three objectives: (1) to analyse the impact of breast cancer screening on breast cancer mortality according to different screening strategies (age group

1996 Health Technology Assessment (HTA) Database.

3407. The impact of maternal age on the cost effectiveness of Down's syndrome screening

The impact of maternal age on the cost effectiveness of Down's syndrome screening The impact of maternal age on the cost effectiveness of Down's syndrome screening The impact of maternal age on the cost effectiveness of Down's syndrome screening Torgerson D J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical (...) assessment on the reliability of the study and the conclusions drawn. Health technology Down's syndrome screening. Type of intervention Screening. Economic study type Cost-effectiveness analysis. Study population Pregnant women between 15 and 50 years old. Setting The setting was not specified. Screening was probably performed in the primary care setting. The study was carried out in the UK. Dates to which data relate The effectiveness data were taken from a study published in 1992 and price data seem

1996 NHS Economic Evaluation Database.

3408. The cost-effectiveness of mammography screening: evidence from a microsimulation model for New Zealand

The cost-effectiveness of mammography screening: evidence from a microsimulation model for New Zealand The cost-effectiveness of mammography screening: evidence from a microsimulation model for New Zealand The cost-effectiveness of mammography screening: evidence from a microsimulation model for New Zealand Szeto K L, Devlin N J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Mammography screening. Type of intervention Screening. Economic study type Cost-effectiveness analysis. Study population Three different age groups of women were considered: 50-64, 50-69 and 45-64 years (women born between 1927 and 1980). Setting Tertiary care centre/hospital. The economic study was carried out in New Zealand. Dates to which data

1996 NHS Economic Evaluation Database.

3409. Screening for abdominal aortic aneurysm: a computer assisted cost-utility analysis

Screening for abdominal aortic aneurysm: a computer assisted cost-utility analysis Screening for abdominal aortic aneurysm: a computer assisted cost-utility analysis Screening for abdominal aortic aneurysm: a computer assisted cost-utility analysis St Leger A S, Spencely M, McCollum C N, Mossa M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions (...) followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Ultrasound screening to detect asymptomatic aortic aneurysms (AAA). Following screening, patients at low risk (AAA smaller than 6cm) would be screened annually and patients at high risk (AAA 6cm or greater) would be offered elective surgery. Type of intervention Prevention and treatment. Economic study type Cost-effectiveness analysis. Study population Hypothetical cohort of 2,500

1996 NHS Economic Evaluation Database.

3410. Screening of coronary artery disease: is there a cost-effective way to do it?

Screening of coronary artery disease: is there a cost-effective way to do it? Screening of coronary artery disease: is there a cost-effective way to do it? Screening of coronary artery disease: is there a cost-effective way to do it? Stanford W Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment (...) on the reliability of the study and the conclusions drawn. Health technology Screening tests in the diagnosis of coronary artery disease (CAD). The following tests were compared: stress electrocardiogram (ECG), stress thallium, stress echocardiogram, positron emission tomography (PET), ultrafast computed tomography (UFCT), and cardiac catheterization with coronary arteriography. Type of intervention Screening and diagnosis. Economic study type Cost-effectiveness analysis. Study population Individuals with high

1996 NHS Economic Evaluation Database.

3411. Cost-effectiveness of breast cancer screening in Spain

Cost-effectiveness of breast cancer screening in Spain Cost-effectiveness of breast cancer screening in Spain Cost-effectiveness of breast cancer screening in Spain Plans P, Casademont L, Salleras L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions (...) drawn. Health technology Screening for breast cancer. The screening procedure was divided into two stages: (a) mammography and clinical examination and (b) medical re-examination and biopsy (a biopsy was undertaken in those women with a positive medical re-examination). Type of intervention Screening. Economic study type Cost-effectiveness analysis. Study population A hypothetical cohort of women aged 50-64 in Spain. Setting Institution (primary health care centres). The economic analysis

1996 NHS Economic Evaluation Database.

3412. Screening for obstructive sleep apnea in patients presenting for snoring surgery

Screening for obstructive sleep apnea in patients presenting for snoring surgery Screening for obstructive sleep apnea in patients presenting for snoring surgery Screening for obstructive sleep apnea in patients presenting for snoring surgery Pradhan P S, Gliklich R E, Winkelman J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Using clinical data alone or oximetry and clinical data in the screening to identify obstructive sleep apnea (OSA) in patients presenting for snoring surgery. Type of intervention Screening. Economic study type Cost-effectiveness analysis. Study population Patient presenting for snoring surgery. Setting Hospital. The economic study was carried out in Philadelphia, USA. Dates to which data relate

1996 NHS Economic Evaluation Database.

3413. Costs and cost effectiveness of cardiovascular screening and intervention: the British family heart study

Costs and cost effectiveness of cardiovascular screening and intervention: the British family heart study Costs and cost effectiveness of cardiovascular screening and intervention: the British family heart study Costs and cost effectiveness of cardiovascular screening and intervention: the British family heart study Wonderling D, McDermott C, Buxton M, Kinmonth A L, Pyke S, Thompson S, Wood D Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Cardiovascular screening and intervention by nurses and, when necessary, onward referral to GPs for prescribing of antihypertensive, lipid lowering, diabetic, HRT, and other drugs. Type of intervention Screening. Economic study type Cost-effectiveness analysis. Study population Men

1996 NHS Economic Evaluation Database.

3414. A cost-effectiveness evaluation of preoperative type-and-screen testing for vaginal hysterectomy

A cost-effectiveness evaluation of preoperative type-and-screen testing for vaginal hysterectomy A cost-effectiveness evaluation of preoperative type-and-screen testing for vaginal hysterectomy A cost-effectiveness evaluation of preoperative type-and-screen testing for vaginal hysterectomy Ransom S B, McNeeley S G, Malone J M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology To evaluate the efficiency of preoperative type-and-screen test for vaginal hysterectomy. Type of intervention Screening. Economic study type Cost-effectiveness analysis. Study population A cohort of female patients who underwent vaginal hysterectomies for all noncancerous indications, including fibroid uterus, endometriosis, menorrhagia, uterine prolapse

1996 NHS Economic Evaluation Database.

3415. Screening for diabetic retinopathy: a quantitative overview of the evidence, applied to the populations of health authorities and boards

Screening for diabetic retinopathy: a quantitative overview of the evidence, applied to the populations of health authorities and boards Screening for diabetic retinopathy: a quantitative overview of the evidence, applied to the populations of health authorities and boards Screening for diabetic retinopathy: a quantitative overview of the evidence, applied to the populations of health authorities and boards Bachmann M, Nelson S Authors' objectives To provide evidence of population requirements (...) for diabetic retinopathy screening, in terms of the burden of illness, and the effectiveness and efficiency of the diagnostic and therapeutic measures available. Searching MEDLINE, EMBASE and ISI databases were searched from 1980 to March 1996; the primary search terms were provided. Study selection Study designs of evaluations included in the review No inclusion criteria relating to the study design were specified for diagnostic accuracy studies. Studies of treatment effectiveness were included only

1996 DARE.

3416. Dual reading in a non-specialized breast cancer screening programme

Dual reading in a non-specialized breast cancer screening programme Dual reading in a non-specialized breast cancer screening programme Dual reading in a non-specialized breast cancer screening programme Seradour B, Wait S, Jacquemier J, Dubuc M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment (...) on the reliability of the study and the conclusions drawn. Health technology Dual reading of mammograms as part of a breast cancer screening programme. Dual reading involves an initial interpretation of screens by one of 120 radiologists practising in the public or private sector and a second interpretation of screens by one of six expert radiologists. Type of intervention Screening; Diagnosis. Economic study type Cost-effectiveness analysis. Study population Women aged 50-69 years from one district in France

1996 NHS Economic Evaluation Database.

3417. Fecal screening tests in the approach to acute infectious diarrhea: a scientific overview

Fecal screening tests in the approach to acute infectious diarrhea: a scientific overview Fecal screening tests in the approach to acute infectious diarrhea: a scientific overview Fecal screening tests in the approach to acute infectious diarrhea: a scientific overview Huicho L, Campos M, Rivera J, Guerrant R L Authors' objectives To evaluate the value of faecal leukocyte, faecal occult blood, faecal lactoferrin, and a combination of faecal leukocytes with clinical data in the workup (...) diagnostic tests were performed without medical supervision were also excluded. Specific interventions included in the review Articles including information on clinical data and/or faecal screening tests (faecal leukocytes, faecal occult blood, faecal lactoferrin), assessed individually or in combination, were eligible for inclusion. Reference standard test against which the new test was compared The included studies were required to use stool culture in all patients as the reference standard. Diarrhoea

1996 DARE.

3418. Cost-effectiveness analysis of screening by faecal occult blood testing for colorectal cancer in Australia

Cost-effectiveness analysis of screening by faecal occult blood testing for colorectal cancer in Australia Cost-effectiveness analysis of screening by faecal occult blood testing for colorectal cancer in Australia Cost-effectiveness analysis of screening by faecal occult blood testing for colorectal cancer in Australia Salkeld G, Young G, Irwig L, Haas M, Glasziou P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each (...) abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology A population-based faecal occult blood test (FOBT) to screen for colorectal cancer, with follow-up of positives by colonoscopy. Type of intervention Screening. Economic study type Cost-effectiveness analysis. Study population Individuals between 50 to 80 years of age. Setting Primary care. The trial

1996 NHS Economic Evaluation Database.

3419. Antithrombotic strategy after total hip replacement: a cost-effectiveness analysis comparing prolonged oral anticoagulants with screening for deep vein thrombosis

Antithrombotic strategy after total hip replacement: a cost-effectiveness analysis comparing prolonged oral anticoagulants with screening for deep vein thrombosis Antithrombotic strategy after total hip replacement: a cost-effectiveness analysis comparing prolonged oral anticoagulants with screening for deep vein thrombosis Antithrombotic strategy after total hip replacement: a cost-effectiveness analysis comparing prolonged oral anticoagulants with screening for deep vein thrombosis Sarasin F (...) P, Bounameaux H Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Prolonged oral anticoagulant therapy was compared with screening in the prevention of deep vein thrombosis (DVT) after total hip replacement. Type of intervention

1996 NHS Economic Evaluation Database.

3420. Costs and benefits of cervical screening. III: Cost/benefit analysis of a call of previously unscreened women

Costs and benefits of cervical screening. III: Cost/benefit analysis of a call of previously unscreened women Costs and benefits of cervical screening. III: Cost/benefit analysis of a call of previously unscreened women Costs and benefits of cervical screening. III: Cost/benefit analysis of a call of previously unscreened women Waugh N, Smith I, Robertson A, Reid G S, Halkerston R, Grant A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Cervical screening of women with no record of a previous smear. Type of intervention Primary prevention. Economic study type Cost-effectiveness analysis. Study population Women with no record of a previous smear. Setting Hospital. The economic study was set in Tayside, UK. Dates to which

1996 NHS Economic Evaluation Database.